About Synairgen plc
Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls). Using the BioBank, Synairgen has a number of tissue models, which include In vitro and Ex vivo models. IFN-b is offered for the treatment or prevention of asthma exacerbations caused by the common cold, and is in Clinical Phase II stage. IFN-b is provided for the treatment or prevention of COPD exacerbations caused by the common cold, and is in Clinical Phase I stage.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: SNG
- CUSIP:
Key Metrics:
- Previous Close: $0.42
- 50 Day Moving Average: $34.30
- 200 Day Moving Average: $30.49
- 52-Week Range: GBX 19 - GBX 38
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $29.69M
- Outstanding Shares: 91,340,000
Additional Links:
Consensus Ratings for Synairgen plc (LON:SNG) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | GBX 91.50 |
Analysts' Ratings History for Synairgen plc (LON:SNG)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 9/22/2016 | N+1 Singer | Lower Price Target | Buy | GBX 47 -> GBX 46 |  |
| 9/22/2016 | FinnCap | Reiterated Rating | Corporate | GBX 137 | |
(Data available from 9/28/2014 forward)
Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Synairgen plc (LON:SNG)Current Year EPS Consensus Estimate: $-3.57 EPS
Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Synairgen plc (LON:SNG)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/11/2015 | Shaw,Simon J B | Insider | Buy | 65,217 | GBX 23 | £14,999.91 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Synairgen plc (LON:SNG)
